Completed
TPMT Activity in 407 New Zealand Patients
Class Central Classrooms beta
YouTube videos curated by Class Central.
Classroom Contents
Advances in Inflammatory Bowel Disease
Automatically move to the next video in the Classroom when playback concludes
- 1 Intro
- 2 Changing Geographic Distribution of IBD
- 3 Main Susceptibility Genes for Crohn's Disease
- 4 Microbial Diversity in Crohn's Disease
- 5 Management of Mild to Moderate UC
- 6 Estimate of Efficacy of AZA for Treatment Success in UC Patients: Meta-Analysis
- 7 Infliximab for UC: ACT 1 and ACT 2 Clinical Remission
- 8 ACT1/2 Trials: Survival Free of Colectomy
- 9 Cyclosporine vs. Infliximab for Acute Severe UC Treatment Failure, %
- 10 Management of Crohn's Disease
- 11 Construct of Biologic Agents Used in Crohn's Disease
- 12 Induction of Clinical Remission at Week 4 In Crohn's Disease: Certolizumab, Adalimumab, Infliximab
- 13 Natalizumab (Anti-Alpha 4 Integrin) Therapy for Crohn's Disease
- 14 Baseline Factors Associated with Time to Surgery: Crohn's, Olmsted County, 1970-2004
- 15 Advances in IBD Natural History: Predictors of More Severe Disease
- 16 CT Enterography Healing: Equivalent to Mucosal Healing at Endoscopy?
- 17 TPMT Activity in 407 New Zealand Patients
- 18 Meta-Analysis: Association Between 6-TGN Levels and Clinical Remission
- 19 Effect of Trough Serum Infliximab Concentrations on Clinical Outcome at 52 Weeks
- 20 What Factors influence the Pharmacokinetics of TNF Antagonists?
- 21 Active Monitoring of Anti-TNF Levels May Ensure Durability of Response
- 22 Effect of Concomitant Azathioprine or Methotrexate on Anti-drug Antibodies
